BGB-A317-311
Completed
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Study Overview
Sex:
All 
Age: 18 Years / 75 Years
No Study Documents
Study Overview
Sex:
All
Age: 18 Years / 75 Years
No Study Documents